Lightstone Ventures related stories
All articles and analysis
Lightstone Ventures leads Series B round for CatabasisCatabasis Pharmaceuticals said Friday that it has secured $32.4 million in Series B financing. New investor Lightstone Ventures was the lead investor. Current investors SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures also participated in the round. Headquartered in Cambridge, Mass., Catabasis is a clinical-stage company dedicated to treating inflammatory and metabolic diseases.
Morgenthaler raises $175 mln, rebrands as Canvas Venture FundMorgenthaler Ventures today announced it closed its 10th fund with $175 million in commitments, exceeding its $150 million target, and will now go by the name Canvas Venture Fund to reflect its new focus on early stage tech deals.
Morgenthaler raises $175 mln, tweaks its nameManagement entity retains Morgenthaler name, but new fund is called Canvas Venture Fund to reflect firm’s focus on early stage tech deals
- Morgenthaler Ventures Looks to Raise Up to $200M for IT Fund X
Morgenthaler Ventures has begun the initial steps of looking to raise its 10th fund, an IT-focused, early stage fund with a hard cap of $200 million, according to an LP source familiar with the fundraising effort.
- Lightstone Raising $200M Fund
Life sciences VCs finally seem to have found their footing. Lightstone Ventures, the firm founded by Morgenthaler Ventures and Advanced Technology Ventures, is raising a fund of up to $200 million.